Dual Immunotherapy Active vs Sunitinib for PD-L1+ Advanced RCC – Cancer Therapy Advisor
Oncology Nurse Advisor |
Dual Immunotherapy Active vs Sunitinib for PD-L1+ Advanced RCC
Cancer Therapy Advisor Atezolizumab (Tecentriq) combined with bevacizumab (Avastin) demonstrated antitumor activity compared with sunitinib as first-line therapy. ORLANDO, FL – Atezolizumab (Tecentriq) combined with bevacizumab (Avastin) demonstrated antitumor activity … GUCS 2017: Early Immunotherapy Discontinuation in mRCCOncology Nurse Advisor |
|
Thou shalt not judge: Silencing your inner attacker
Fairfield Daily Republic It’s the ability to capture the moment in suspended animation without judgment. Common humanity is the acknowledgement of the human context – that making mistakes, falling and being afraid are uniquely human experiences. We all doubt ourselves … |
|
Thou shalt not judge: Silencing your inner attacker
Fairfield Daily Republic It’s the ability to capture the moment in suspended animation without judgment. Common humanity is the acknowledgement of the human context – that making mistakes, falling and being afraid are uniquely human experiences. We all doubt ourselves … |